PTI-2

PTI-2
Legal status
Legal status
Identifiers
IUPAC name
  • N-(2-methoxyethyl)-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)propan-2-amine
CAS Number
ChemSpider
UNII
Chemical and physical data
FormulaC23H33N3OS
Molar mass399.60 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCN1C=C(C2=CC=CC=C21)C3=NC(CN(C(C)C)CCOC)=CS3
InChI
  • InChI=1S/C23H33N3OS/c1-5-6-9-12-26-16-21(20-10-7-8-11-22(20)26)23-24-19(17-28-23)15-25(18(2)3)13-14-27-4/h7-8,10-11,16-18H,5-6,9,12-15H2,1-4H3
  • Key:PSAKYYVEVVAWJL-UHFFFAOYSA-N

PTI-2 (SGT-49) is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-1. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4]

See also

References

  1. ↑ "PTI-2". Cayman Chemical. Retrieved 8 July 2015.
  2. ↑ US 7700634, Adam-Worrall J, Morrison AJ, Wishart G, Kiyoi T, McArthur DR, "(Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor.", issued 20 April 2010, assigned to Organon NV
  3. ↑ US 7763732, Paul David Ratcliffe PD, Adam-Worrall J, Morrison AJ, Francis SJ, Kiyoi T, "Indole Derivatives", issued 27 July 2010, assigned to Organon NV
  4. ↑ Kiyoi T, Adam JM, Clark JK, Davies K, Easson AM, Edwards D, et al. (March 2011). "Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists". Bioorganic & Medicinal Chemistry Letters. 21 (6): 1748–53. doi:10.1016/j.bmcl.2011.01.082. PMID 21316962.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.